Septic ShockSshOCTANCT04593212
Assessment of Microcirculatory Dysfunction in Septic Shock Patients by OCTA
An observational study of Septic Shock, run by Hospital da Luz, Portugal at 1 site in Portugal.
Trial summary
Purpose and rationale: Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. Sepsis and septic shock are major public health problems killing one in every three patients. Microcirculatory dysfunction is frequent in septic shock. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Septic Shock
- What is being tested?
- Optical Coherence Tomography Angiography
- How many people
- 30 participants
- Where
- 1 sitePortugal
- Study dates
- 16 Feb 2023to 31 Jan 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Source population: 1. Cross-sectional case-control study: we intend to enrol 30 septic shock patients and 30 healthy controls. 2. Prospective cohort study: we intend to enrol 165 septic shock patients (the first 30 patients will be the same from the cross-sectional case-control study). The enrolment will take place from patients admitted to the Intensive Care Medicine Department of Hospital da Luz Lisboa, from February 2021 to February 2022. The healthy controls will be enrolled from our hospital staff.
Who may be able to join
- ≥ 18 years-old
- septic shock diagnosis (defined by the presence of sepsis according to Sepsis-3 definition plus a SOFA score ≥ 3 points at cardiovascular system despite adequate volume resuscitation) less than 24 hours before the first OCTA assessment
Who cannot join
- Inability or willingness to provide informed consent from the patient or next of kin
- Shock due to any other cause without septic shock
- Bilateral eye absence
- Previously known retinopathy
- Previous retinal surgery or photocoagulation
- Pregnant women
- Participants with psychiatry disorders
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Improving the Assessment of Microcirculatory Dysfunction in Septic Shock Patients Using Optical Coherence Tomography Angiography at the Bedside
Purpose and rationale: Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. Sepsis and septic shock are major public health problems killing one in every three patients. Microcirculatory dysfunction is frequent in septic shock. The duration and severity of this dysfunction have a prognostic impact by being associated with organ failure and mortality. Our study purposes to demonstrate the feasibility of optical coherence tomography angiography (OCTA) to improve assessment of microcirculatory dysfunction by showing that retinal and choroidal microcirculatory changes with prognostic impact are present during septic shock.
Primary objective: To characterize the alterations of retinal and choroidal microcirculation in septic shock.
Read more
We will test the hypothesis that retinal and/or choroidal microcirculation shows dysfunctional changes (lower vascular density, lower percentage of perfused small vessel, lower blood flow index and higher vascular heterogeneity) in septic shock patients.
Secondary objective: To test the prognostic value of retinal and choroidal microcirculatory dysfunction in septic shock.
We will test the hypothesis that higher magnitude and persistence of retinal and/or choroidal microcirculatory dysfunction beyond the successful macro-hemodynamic resuscitation are independent predictors of organ failure and mortality in septic shock patients.
Study type: Two sequential observational studies.
Study design: A cross-sectional case-control study followed by a prospective cohort study with a 90-days longitudinal follow-up period.
Study population: 165 septic shock patients and 30 healthy controls.
Study duration: 90 days from enrolment to final follow-up assessment. One to two years of enrolment.
Read the detailed description
Purpose and rationale: Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. Sepsis and septic shock are major public health problems killing one in every three patients. Microcirculatory dysfunction is frequent in septic shock. The duration and severity of this dysfunction have a prognostic impact by being associated with organ failure and mortality. Our study purposes to demonstrate the feasibility of OCTA to improve assessment of microcirculatory dysfunction by showing that retinal and choroidal microcirculatory changes with prognostic impact are present during septic shock.
Primary objective (specific aim 1): To characterize the alterations of retinal and choroidal microcirculation in septic shock.
We will test the hypothesis that retinal and/or choroidal microcirculation shows dysfunctional changes (lower vascular density, lower percentage of perfused small vessel, lower blood flow index and higher vascular heterogeneity) in septic shock patients.
Secondary objective (specific aim 2): To test the prognostic value of retinal and choroidal microcirculatory dysfunction in septic shock.
We will test the hypothesis that higher magnitude and persistence of retinal and/or choroidal microcirculatory dysfunction beyond the successful macro-hemodynamic resuscitation are independent predictors of organ failure and mortality in septic shock patients.
Study type: Two sequential observational studies.
Study design: A cross-sectional case-control study followed by a prospective cohort study with a 90-days longitudinal follow-up period.
Study population: 165 septic shock patients and 30 healthy controls. Power and sample size calculations: Based on sublingual percentage of perfused small vessel (PPV) difference previously reported between septic shock patients and healthy controls (60% vs. 95%), we estimate that we will need to enrol 27 patients and 27 controls to demonstrate the same difference at the retina and choroid. To show a PPV difference between survivors and non-survivors (70% vs. 46%) in the septic shock group, also based on previous reports at the sublingual microcirculatory level, we estimate that we will need to enrol 150 septic shock patients. These calculations assumed an alpha level of 0.05 and a power of 80%. Our Department admits about 200 septic shock patients annually, so to account for drop-outs and limitations with enrolment (10-20% refusal to participate) we decided to increase our enrolment goal by 10% to 165 septic shock patients and 30 healthy controls.
Recruitment and inform consent: Recruitment will take place at the Intensive Care Medicine Department of Hospital da Luz Lisboa. Patients admitted to the Department with the diagnosis of septic shock will be screened for eligibility. If the patients are eligible to participate, they will be invited to enrol in the study by the principal investigator or other ICU medical team member. The study objectives and procedures will be explained to them. If the patient agrees to participate in the study, a written informed consent will be sign before enrolment. If the patient is unable to give informed consent to participate in the study, it will be asked to the reference next of kin using the same procedures as described before.
Study duration: 90 days from enrolment to final follow-up assessment. One to two years of enrolment.
Study procedures:
Baseline Assessment: After confirmation of eligibility and enrolment in the studies, demographic data (age, gender), type of admission (urgent/elective, medical/surgical/trauma), patient origin (emergency department, ward, operation room), source of infection (lung, urinary tract, intra-abdominal, skin and soft tissues, others), prognostic scores (APACHE II, SAPS II) and organic dysfunction scores (SOFA, quick SOFA) will be collected at baseline for septic shock patients.
Study Assessments:
OCTA: OCTA examination will be performed daily to septic shock patients from day 1 (less than 24 hours after diagnosis) until successful shock resolution (weaning from vasopressors) or until a maximum of 7 days. The healthy controls will be submitted to a single OCTA evaluation. We will use the Cirrus 6000® OCTA system (ZEISS, Germany) and the interpretation of OCTA images will be performed by two independent specialized ophthalmologists blinded to the clinical condition of patients. Images will be stored at the device working station.
Hemodynamic assessment: Every septic shock patient will have a central venous catheter and an arterial line in place according to the standard of care. Daily, during or within a maximum of 1 hour of OCTA examination, we will record the values of temperature, heart rate, mean arterial pressure, capillary refill time, central venous pressure, cardiac index, pH, PaCO2, PaO2, PvCO2, SaO2, SvO2, haemoglobin, serum lactate, fluid balance, oxygen delivery, oxygen consumption and oxygen extraction ratio.
Vasoactive and sedo-analgesic drugs: Daily we will record the vasoactive and sedo-analgesic drugs administered to septic shock patients and its total daily dose until complete weaning (defined as 24 hours free of vasopressors). Daily vasopressor score will also be calculated as suggested by Póvoa, P. et al.
Ventilatory and renal replacement therapy support: Daily we will record the type of ventilatory support (oxygen therapy, high flow oxygen therapy, non-invasive ventilation, invasive ventilation) and of renal replacement therapy (continuous, sustained low-efficiency, intermittent) used, if needed, until complete weaning.
Data analysis: In both studies, we will perform a descriptive statistical analysis of studied variables. Comparisons between healthy controls (single OCTA) and septic shock patients (first OCTA) to address endpoints related to specific aim 1 will be performed using t-Student test or Mann-Whitney test as appropriate. To address endpoints related to specific aim 2, we will compare survivors to non-survivors by doing a survival analysis using Kaplan-Meyer curves and Cox proportional hazards multivariable regression with microcirculatory measures as predictors. Additional comparisons will be performed using χ2 test, t-Student test, Mann-Whitney test and logistic regression as appropriate. We will assess confounding by adding significant variables in the regression models. We intend to perform a prespecified subgroup analysis of septic shock patients by serum lactate <4mmol/L vs. ≥4mmol/L and <2mmol/L vs. ≥2mmol/L. The correlation between retinal and choroidal microcirculation variables and macrohemodynamic variables will be assessed by the Spearman rank correlation coefficient. Area under Receiver Operating Characteristic curve of OCTA for prognostic outcomes will be calculated. A p-value < 0.05 will be considered statistically significant. Statistical analysis will be performed with STATA® 15 (StataCorp, Texas, USA).
- Conditions
- Septic Shock
- Being tested
- Optical Coherence Tomography Angiography
- Medical subject headings
- Shock, Septic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Optical Coherence Tomography AngiographyDiagnostic test
Evaluation of microcirculatory dysfunction by assessment of retinal and choroidal microvasculature with optical coherence tomography angiography (OCTA)
| Study group | Role | What they receive |
|---|---|---|
| Septic Shock Survivors | Not described Receives: Diagnostic Test: Optical Coherence Tomography Angiography | |
| Septic Shock Non-Survivors | Not described Receives: Diagnostic Test: Optical Coherence Tomography Angiography |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Perfused Small Vessel (PPV)
The absolute number of completely perfused small vessels (diameter < 20μm) divided by the absolute number of small vessels (diameter < 20μm).
Measured: Daily assessment from day 0 to a maximum of 7 days
28-days All-Cause Mortality
Measured: 28-days after enrollment
Secondary outcomes (10)
Perfused Small Vessel Density (PVD)
The percentage area occupied by the small vessels (diameter <20μm)
Measured: Daily assessment from day 0 to a maximum of 7 days
Blood Flow Index (BFI)
The average flow signal
Measured: Daily assessment from day 0 to a maximum of 7 days
Heterogeneity Index
The difference between the highest and the lowest BFI divided by the mean BFI
Measured: Daily assessment from day 0 to a maximum of 7 days
ICU mortality
Measured: 90-days after enrollment
Hospital mortality
Measured: 90-days after enrollment
ICU length of stay
Measured: 90-days after enrollment
Hospital length of stay
Measured: 90-days after enrollment
Ventilator free-days
Measured: 90-days after enrollment
Vasopressor free-days
Measured: 90-days after enrollment
Renal replacement therapy free-days
Measured: 90-days after enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Oct 2020
- Study start16 Feb 2023
- Primary completion31 Oct 2024
- Study completion31 Jan 2025
Why it stopped: Completed the case-control study (30 patients and 30 controls). The prospective cohort component was discontinued due to slow recruitment and funding constraints.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (15)Papers the sponsor has linked to this study.
- Other trials for Septic ShockStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hospital da Luz, Portugal
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- André Alexandre, MD, Principal investigator, 11170
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04593212
- Sponsor's protocol ID
- id.215
- Acronym
- SshOCTA
- Status last verified
- Sep 2026
- First submitted
- 13 Oct 2020
- Last updated
- 18 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
De Backer D, Cecconi M, Lipman J, Machado F, Myatra SN, Ostermann M, Perner A, Teboul JL, Vincent JL, Walley KR. Challenges in the management of septic shock: a narrative review. Intensive Care Med. 2019 Apr;45(4):420-433. doi: 10.1007/s00134-019-05544-x. Epub 2019 Feb 11.
PubMed 30741328Lipinska-Gediga M. Sepsis and septic shock-is a microcirculation a main player? Anaesthesiol Intensive Ther. 2016;48(4):261-265. doi: 10.5603/AIT.a2016.0037. Epub 2016 Sep 23.
PubMed 27660252Ince C. Hemodynamic coherence and the rationale for monitoring the microcirculation. Crit Care. 2015;19 Suppl 3(Suppl 3):S8. doi: 10.1186/cc14726. Epub 2015 Dec 18.
PubMed 26729241Ait-Oufella H, Bourcier S, Lehoux S, Guidet B. Microcirculatory disorders during septic shock. Curr Opin Crit Care. 2015 Aug;21(4):271-5. doi: 10.1097/MCC.0000000000000217.
PubMed 26103150Ince C. The rationale for microcirculatory guided fluid therapy. Curr Opin Crit Care. 2014 Jun;20(3):301-8. doi: 10.1097/MCC.0000000000000091.
PubMed 24758985De Backer D, Donadello K, Sakr Y, Ospina-Tascon G, Salgado D, Scolletta S, Vincent JL. Microcirculatory alterations in patients with severe sepsis: impact of time of assessment and relationship with outcome. Crit Care Med. 2013 Mar;41(3):791-9. doi: 10.1097/CCM.0b013e3182742e8b.
PubMed 23318492Spaide RF, Fujimoto JG, Waheed NK, Sadda SR, Staurenghi G. Optical coherence tomography angiography. Prog Retin Eye Res. 2018 May;64:1-55. doi: 10.1016/j.preteyeres.2017.11.003. Epub 2017 Dec 8.
PubMed 29229445Onishi AC, Fawzi AA. An overview of optical coherence tomography angiography and the posterior pole. Ther Adv Ophthalmol. 2019 Apr 3;11:2515841419840249. doi: 10.1177/2515841419840249. eCollection 2019 Jan-Dec.
PubMed 30984909Sambhav K, Grover S, Chalam KV. The application of optical coherence tomography angiography in retinal diseases. Surv Ophthalmol. 2017 Nov-Dec;62(6):838-866. doi: 10.1016/j.survophthal.2017.05.006. Epub 2017 Jun 1.
PubMed 28579550Alnawaiseh M, Ertmer C, Seidel L, Arnemann PH, Lahme L, Kampmeier TG, Rehberg SW, Heiduschka P, Eter N, Hessler M. Feasibility of optical coherence tomography angiography to assess changes in retinal microcirculation in ovine haemorrhagic shock. Crit Care. 2018 May 29;22(1):138. doi: 10.1186/s13054-018-2056-3.
PubMed 29843760Erikson K, Liisanantti JH, Hautala N, Koskenkari J, Kamakura R, Herzig KH, Syrjala H, Ala-Kokko TI. Retinal arterial blood flow and retinal changes in patients with sepsis: preliminary study using fluorescein angiography. Crit Care. 2017 Apr 10;21(1):86. doi: 10.1186/s13054-017-1676-3.
PubMed 28395665De Backer D, Creteur J, Preiser JC, Dubois MJ, Vincent JL. Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med. 2002 Jul 1;166(1):98-104. doi: 10.1164/rccm.200109-016oc.
PubMed 12091178Sakr Y, Dubois MJ, De Backer D, Creteur J, Vincent JL. Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. Crit Care Med. 2004 Sep;32(9):1825-31. doi: 10.1097/01.ccm.0000138558.16257.3f.
PubMed 15343008Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287.
PubMed 26903338Povoa P, Salluh JI, Martinez ML, Guillamat-Prats R, Gallup D, Al-Khalidi HR, Thompson BT, Ranieri VM, Artigas A. Clinical impact of stress dose steroids in patients with septic shock: insights from the PROWESS-Shock trial. Crit Care. 2015 Apr 28;19(1):193. doi: 10.1186/s13054-015-0921-x.
PubMed 25928214
Study at a glance
From the registry record, last updated by the sponsor on 18 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Improving the Assessment of Microcirculatory Dysfunction in Septic Shock Patients Using Optical Coherence Tomography Angiography at the Bedside
- ClinicalTrials.gov ID
- NCT04593212
- Acronym / sponsor ID
- SshOCTA / id.215
- Conditions
- Septic Shock
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: Completed the case-control study (30 patients and 30 controls). The prospective cohort component was discontinued due to slow recruitment and funding constraints.
- Enrolment
- 30 participants (actual)
- Lead sponsor
- Hospital da Luz, PortugalUniversity, hospital or other
- Study start
- 16 Feb 2023 (actual)
- Primary completion
- 31 Oct 2024 (actual)
- Study completion
- 31 Jan 2025 (actual)
- First posted
- 19 Oct 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Purpose and rationale: Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. Sepsis and septic shock are major public health problems killing one in every three patients. Microcirculatory dysfunction is frequent in septic shock. The duration and severity of this dysfunction have a prognostic impact by being associated with organ failure and mortality. Our study purposes to demonstrate the feasibility of optical coherence tomography angiography (OCTA) to improve assessment of microcirculatory dysfunction by showing that retinal and choroidal microcirculatory changes with prognostic impact are present during septic shock.
Primary objective: To characterize the alterations of retinal and choroidal microcirculation in septic shock.
We will test the hypothesis that retinal and/or choroidal microcirculation shows dysfunctional changes (lower vascular density, lower percentage of perfused small vessel, lower blood flow index and higher vascular heterogeneity) in septic shock patients.
Secondary objective: To test the prognostic value of retinal and choroidal microcirculatory dysfunction in septic shock.
We will test the hypothesis that higher magnitude and persistence of retinal and/or choroidal microcirculatory dysfunction beyond the successful macro-hemodynamic resuscitation are independent predictors of organ failure and mortality in septic shock patients.
Study type: Two sequential observational studies.
Study design: A cross-sectional case-control study followed by a prospective cohort study with a 90-days longitudinal follow-up period.
Study population: 165 septic shock patients and 30 healthy controls.
Study duration: 90 days from enrolment to final follow-up assessment. One to two years of enrolment.
Detailed description
Purpose and rationale: Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. Sepsis and septic shock are major public health problems killing one in every three patients. Microcirculatory dysfunction is frequent in septic shock. The duration and severity of this dysfunction have a prognostic impact by being associated with organ failure and mortality. Our study purposes to demonstrate the feasibility of OCTA to improve assessment of microcirculatory dysfunction by showing that retinal and choroidal microcirculatory changes with prognostic impact are present during septic shock.
Primary objective (specific aim 1): To characterize the alterations of retinal and choroidal microcirculation in septic shock.
We will test the hypothesis that retinal and/or choroidal microcirculation shows dysfunctional changes (lower vascular density, lower percentage of perfused small vessel, lower blood flow index and higher vascular heterogeneity) in septic shock patients.
Secondary objective (specific aim 2): To test the prognostic value of retinal and choroidal microcirculatory dysfunction in septic shock.
We will test the hypothesis that higher magnitude and persistence of retinal and/or choroidal microcirculatory dysfunction beyond the successful macro-hemodynamic resuscitation are independent predictors of organ failure and mortality in septic shock patients.
Study type: Two sequential observational studies.
Study design: A cross-sectional case-control study followed by a prospective cohort study with a 90-days longitudinal follow-up period.
Study population: 165 septic shock patients and 30 healthy controls. Power and sample size calculations: Based on sublingual percentage of perfused small vessel (PPV) difference previously reported between septic shock patients and healthy controls (60% vs. 95%), we estimate that we will need to enrol 27 patients and 27 controls to demonstrate the same difference at the retina and choroid. To show a PPV difference between survivors and non-survivors (70% vs. 46%) in the septic shock group, also based on previous reports at the sublingual microcirculatory level, we estimate that we will need to enrol 150 septic shock patients. These calculations assumed an alpha level of 0.05 and a power of 80%. Our Department admits about 200 septic shock patients annually, so to account for drop-outs and limitations with enrolment (10-20% refusal to participate) we decided to increase our enrolment goal by 10% to 165 septic shock patients and 30 healthy controls.
Recruitment and inform consent: Recruitment will take place at the Intensive Care Medicine Department of Hospital da Luz Lisboa. Patients admitted to the Department with the diagnosis of septic shock will be screened for eligibility. If the patients are eligible to participate, they will be invited to enrol in the study by the principal investigator or other ICU medical team member. The study objectives and procedures will be explained to them. If the patient agrees to participate in the study, a written informed consent will be sign before enrolment. If the patient is unable to give informed consent to participate in the study, it will be asked to the reference next of kin using the same procedures as described before.
Study duration: 90 days from enrolment to final follow-up assessment. One to two years of enrolment.
Study procedures:
Baseline Assessment: After confirmation of eligibility and enrolment in the studies, demographic data (age, gender), type of admission (urgent/elective, medical/surgical/trauma), patient origin (emergency department, ward, operation room), source of infection (lung, urinary tract, intra-abdominal, skin and soft tissues, others), prognostic scores (APACHE II, SAPS II) and organic dysfunction scores (SOFA, quick SOFA) will be collected at baseline for septic shock patients.
Study Assessments:
OCTA: OCTA examination will be performed daily to septic shock patients from day 1 (less than 24 hours after diagnosis) until successful shock resolution (weaning from vasopressors) or until a maximum of 7 days. The healthy controls will be submitted to a single OCTA evaluation. We will use the Cirrus 6000® OCTA system (ZEISS, Germany) and the interpretation of OCTA images will be performed by two independent specialized ophthalmologists blinded to the clinical condition of patients. Images will be stored at the device working station.
Hemodynamic assessment: Every septic shock patient will have a central venous catheter and an arterial line in place according to the standard of care. Daily, during or within a maximum of 1 hour of OCTA examination, we will record the values of temperature, heart rate, mean arterial pressure, capillary refill time, central venous pressure, cardiac index, pH, PaCO2, PaO2, PvCO2, SaO2, SvO2, haemoglobin, serum lactate, fluid balance, oxygen delivery, oxygen consumption and oxygen extraction ratio.
Vasoactive and sedo-analgesic drugs: Daily we will record the vasoactive and sedo-analgesic drugs administered to septic shock patients and its total daily dose until complete weaning (defined as 24 hours free of vasopressors). Daily vasopressor score will also be calculated as suggested by Póvoa, P. et al.
Ventilatory and renal replacement therapy support: Daily we will record the type of ventilatory support (oxygen therapy, high flow oxygen therapy, non-invasive ventilation, invasive ventilation) and of renal replacement therapy (continuous, sustained low-efficiency, intermittent) used, if needed, until complete weaning.
Data analysis: In both studies, we will perform a descriptive statistical analysis of studied variables. Comparisons between healthy controls (single OCTA) and septic shock patients (first OCTA) to address endpoints related to specific aim 1 will be performed using t-Student test or Mann-Whitney test as appropriate. To address endpoints related to specific aim 2, we will compare survivors to non-survivors by doing a survival analysis using Kaplan-Meyer curves and Cox proportional hazards multivariable regression with microcirculatory measures as predictors. Additional comparisons will be performed using χ2 test, t-Student test, Mann-Whitney test and logistic regression as appropriate. We will assess confounding by adding significant variables in the regression models. We intend to perform a prespecified subgroup analysis of septic shock patients by serum lactate <4mmol/L vs. ≥4mmol/L and <2mmol/L vs. ≥2mmol/L. The correlation between retinal and choroidal microcirculation variables and macrohemodynamic variables will be assessed by the Spearman rank correlation coefficient. Area under Receiver Operating Characteristic curve of OCTA for prognostic outcomes will be calculated. A p-value < 0.05 will be considered statistically significant. Statistical analysis will be performed with STATA® 15 (StataCorp, Texas, USA).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Septic Shock Survivors | – | Diagnostic Test: Optical Coherence Tomography Angiography |
| Septic Shock Non-Survivors | – | Diagnostic Test: Optical Coherence Tomography Angiography |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Source population: 1. Cross-sectional case-control study: we intend to enrol 30 septic shock patients and 30 healthy controls. 2. Prospective cohort study: we intend to enrol 165 septic shock patients (the first 30 patients will be the same from the cross-sectional case-control study). The enrolment will take place from patients admitted to the Intensive Care Medicine Department of Hospital da Luz Lisboa, from February 2021 to February 2022. The healthy controls will be enrolled from our hospital staff.
Key inclusion criteria (2 listed)
- ≥ 18 years-old
- septic shock diagnosis (defined by the presence of sepsis according to Sepsis-3 definition plus a SOFA score ≥ 3 points at cardiovascular system despite adequate volume resuscitation) less than 24 hours before the first OCTA assessment
Key exclusion criteria (7 listed)
- Inability or willingness to provide informed consent from the patient or next of kin
- Shock due to any other cause without septic shock
- Bilateral eye absence
- Previously known retinopathy
- Previous retinal surgery or photocoagulation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Optical Coherence Tomography AngiographyEvaluation of microcirculatory dysfunction by assessment of retinal and choroidal microvasculature with optical coherence tomography angiography (OCTA) | Diagnostic test | Septic Shock Non-Survivors, Septic Shock Survivors |
Primary outcome
Percentage of Perfused Small Vessel (PPV)
Time frame: Daily assessment from day 0 to a maximum of 7 days
The absolute number of completely perfused small vessels (diameter < 20μm) divided by the absolute number of small vessels (diameter < 20μm).
28-days All-Cause Mortality
Time frame: 28-days after enrollment
10 secondary outcomes
Perfused Small Vessel Density (PVD)
Time frame: Daily assessment from day 0 to a maximum of 7 days
Blood Flow Index (BFI)
Time frame: Daily assessment from day 0 to a maximum of 7 days
Heterogeneity Index
Time frame: Daily assessment from day 0 to a maximum of 7 days
ICU mortality
Time frame: 90-days after enrollment
Hospital mortality
Time frame: 90-days after enrollment
ICU length of stay
Time frame: 90-days after enrollment
Hospital length of stay
Time frame: 90-days after enrollment
Ventilator free-days
Time frame: 90-days after enrollment
Vasopressor free-days
Time frame: 90-days after enrollment
Renal replacement therapy free-days
Time frame: 90-days after enrollment
Results and safety
The study was stopped early (reason given: Completed the case-control study (30 patients and 30 controls). The prospective cohort component was discontinued due to slow recruitment and funding constraints.). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Sep 2026.
- Background: PubMed 30741328De Backer D, Cecconi M, Lipman J, Machado F, Myatra SN, Ostermann M, Perner A, Teboul JL, Vincent JL, Walley KR. Challenges in the management of septic shock: a narrative review. Intensive Care Med. 2019 Apr;45(4):420-433. doi: 10.1007/s00134-019-05544-x. Epub 2019 Feb 11.
- Background: PubMed 27660252Lipinska-Gediga M. Sepsis and septic shock-is a microcirculation a main player? Anaesthesiol Intensive Ther. 2016;48(4):261-265. doi: 10.5603/AIT.a2016.0037. Epub 2016 Sep 23.
- Background: PubMed 26729241Ince C. Hemodynamic coherence and the rationale for monitoring the microcirculation. Crit Care. 2015;19 Suppl 3(Suppl 3):S8. doi: 10.1186/cc14726. Epub 2015 Dec 18.
- Background: PubMed 26103150Ait-Oufella H, Bourcier S, Lehoux S, Guidet B. Microcirculatory disorders during septic shock. Curr Opin Crit Care. 2015 Aug;21(4):271-5. doi: 10.1097/MCC.0000000000000217.
- Background: PubMed 24758985Ince C. The rationale for microcirculatory guided fluid therapy. Curr Opin Crit Care. 2014 Jun;20(3):301-8. doi: 10.1097/MCC.0000000000000091.
- Background: PubMed 23318492De Backer D, Donadello K, Sakr Y, Ospina-Tascon G, Salgado D, Scolletta S, Vincent JL. Microcirculatory alterations in patients with severe sepsis: impact of time of assessment and relationship with outcome. Crit Care Med. 2013 Mar;41(3):791-9. doi: 10.1097/CCM.0b013e3182742e8b.
- Background: PubMed 29229445Spaide RF, Fujimoto JG, Waheed NK, Sadda SR, Staurenghi G. Optical coherence tomography angiography. Prog Retin Eye Res. 2018 May;64:1-55. doi: 10.1016/j.preteyeres.2017.11.003. Epub 2017 Dec 8.
- Background: PubMed 30984909Onishi AC, Fawzi AA. An overview of optical coherence tomography angiography and the posterior pole. Ther Adv Ophthalmol. 2019 Apr 3;11:2515841419840249. doi: 10.1177/2515841419840249. eCollection 2019 Jan-Dec.
- Background: PubMed 28579550Sambhav K, Grover S, Chalam KV. The application of optical coherence tomography angiography in retinal diseases. Surv Ophthalmol. 2017 Nov-Dec;62(6):838-866. doi: 10.1016/j.survophthal.2017.05.006. Epub 2017 Jun 1.
- Background: PubMed 29843760Alnawaiseh M, Ertmer C, Seidel L, Arnemann PH, Lahme L, Kampmeier TG, Rehberg SW, Heiduschka P, Eter N, Hessler M. Feasibility of optical coherence tomography angiography to assess changes in retinal microcirculation in ovine haemorrhagic shock. Crit Care. 2018 May 29;22(1):138. doi: 10.1186/s13054-018-2056-3.
- Background: PubMed 28395665Erikson K, Liisanantti JH, Hautala N, Koskenkari J, Kamakura R, Herzig KH, Syrjala H, Ala-Kokko TI. Retinal arterial blood flow and retinal changes in patients with sepsis: preliminary study using fluorescein angiography. Crit Care. 2017 Apr 10;21(1):86. doi: 10.1186/s13054-017-1676-3.
- Background: PubMed 12091178De Backer D, Creteur J, Preiser JC, Dubois MJ, Vincent JL. Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med. 2002 Jul 1;166(1):98-104. doi: 10.1164/rccm.200109-016oc.
- Individual participant dataSharing planned: No
Related trials for Septic Shock
Active, not recruitingPhase 4
Thymosin Alpha 1 and IgM Levels in Sepsis
Sepsis, Septic Shock
Not yet recruiting
Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial
Acute-on-Chronic Liver Failure (ACLF)
Not yet recruiting
ICU-SUCCEED for Survivors of Acute Respiratory Failure and Their Caregivers
Acute Respiratory Failure, Critical Illness
Not yet recruitingObservational study
Longitudinal Trajectories of Myocardial Work in Patients With Sepsis
Sepsis, Septic Shock Hyperdynamic
RecruitingObservational study
Immunothrombosis With Septic Shock Undergoing Renal Replacement Therapy With the OXIRIS Membrane
Sepsis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
André Alexandre, MD principal investigator
11170
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Septic Shock, run by Hospital da Luz, Portugal at 1 site in Portugal.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 18 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Portugal. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Completed the case-control study (30 patients and 30 controls). The prospective cohort component was discontinued due to slow recruitment and funding constraints.). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Perfused Small Vessel (PPV) (time frame: Daily assessment from day 0 to a maximum of 7 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04593212, which also lists 15 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2026.